These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 21436469)

  • 1. MDM2 promoter SNP285 and SNP309; phylogeny and impact on cancer risk.
    Knappskog S; Lønning PE
    Oncotarget; 2011 Mar; 2(3):251-8. PubMed ID: 21436469
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The MDM2 promoter SNP285C/309G haplotype diminishes Sp1 transcription factor binding and reduces risk for breast and ovarian cancer in Caucasians.
    Knappskog S; Bjørnslett M; Myklebust LM; Huijts PE; Vreeswijk MP; Edvardsen H; Guo Y; Zhang X; Yang M; Ylisaukko-Oja SK; Alhopuro P; Arola J; Tollenaar RA; van Asperen CJ; Seynaeve C; Staalesen V; Chrisanthar R; Løkkevik E; Salvesen HB; Evans DG; Newman WG; Lin D; Aaltonen LA; Børresen-Dale AL; Tell GS; Stoltenberg C; Romundstad P; Hveem K; Lillehaug JR; Vatten L; Devilee P; Dørum A; Lønning PE
    Cancer Cell; 2011 Feb; 19(2):273-82. PubMed ID: 21316605
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SNP285C modulates oestrogen receptor/Sp1 binding to the MDM2 promoter and reduces the risk of endometrial but not prostatic cancer.
    Knappskog S; Trovik J; Marcickiewicz J; Tingulstad S; Staff AC; ; Romundstad P; Hveem K; Vatten L; Salvesen HB; Lønning PE
    Eur J Cancer; 2012 Sep; 48(13):1988-96. PubMed ID: 22119201
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of MDM2 SNP309 and SNP285 status on the risk of cancer in the breast, prostate, lung and colon.
    Gansmo LB; Knappskog S; Romundstad P; Hveem K; Vatten L; Lønning PE
    Int J Cancer; 2015 Jul; 137(1):96-103. PubMed ID: 25431177
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of the
    Miedl H; Lebhard J; Ehart L; Schreiber M
    Int J Mol Sci; 2019 Jan; 20(3):. PubMed ID: 30691044
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of the MDM2 promoter polymorphisms SNP309T>G and SNP285G>C on the risk of ovarian cancer in BRCA1 mutation carriers.
    Bjørnslett M; Knappskog S; Lønning PE; Dørum A
    BMC Cancer; 2012 Oct; 12():454. PubMed ID: 23039163
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of the MDM2 promoter SNP285 and SNP309 on Sp1 transcription factor binding and cancer risk.
    Knappskog S; Lønning PE
    Transcription; 2011; 2(5):207-10. PubMed ID: 22231115
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Population distribution and ancestry of the cancer protective MDM2 SNP285 (rs117039649).
    Knappskog S; Gansmo LB; Dibirova K; Metspalu A; Cybulski C; Peterlongo P; Aaltonen L; Vatten L; Romundstad P; Hveem K; Devilee P; Evans GD; Lin D; Van Camp G; Manolopoulos VG; Osorio A; Milani L; Ozcelik T; Zalloua P; Mouzaya F; Bliznetz E; Balanovska E; Pocheshkova E; Kučinskas V; Atramentova L; Nymadawa P; Titov K; Lavryashina M; Yusupov Y; Bogdanova N; Koshel S; Zamora J; Wedge DC; Charlesworth D; Dörk T; Balanovsky O; Lønning PE
    Oncotarget; 2014 Sep; 5(18):8223-34. PubMed ID: 25327560
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MDM2 SNP309 is associated with high grade node positive breast tumours and is in linkage disequilibrium with a novel MDM2 intron 1 polymorphism.
    Paulin FE; O'Neill M; McGregor G; Cassidy A; Ashfield A; Ali CW; Munro AJ; Baker L; Purdie CA; Lane DP; Thompson AM
    BMC Cancer; 2008 Oct; 8():281. PubMed ID: 18828900
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A high-frequency regulatory polymorphism in the p53 pathway accelerates tumor development.
    Post SM; Quintás-Cardama A; Pant V; Iwakuma T; Hamir A; Jackson JG; Maccio DR; Bond GL; Johnson DG; Levine AJ; Lozano G
    Cancer Cell; 2010 Sep; 18(3):220-30. PubMed ID: 20832750
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The MDM2 285G-309G haplotype is associated with an earlier age of tumour onset in patients with Li-Fraumeni syndrome.
    Renaux-Petel M; Sesboüé R; Baert-Desurmont S; Vasseur S; Fourneaux S; Bessenay E; Frébourg T; Bougeard G
    Fam Cancer; 2014 Mar; 13(1):127-30. PubMed ID: 23884452
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MDM2 promoter SNP344T>A (rs1196333) status does not affect cancer risk.
    Knappskog S; Gansmo LB; Romundstad P; Bjørnslett M; Trovik J; Sommerfelt-Pettersen J; Løkkevik E; ; Tollenaar RA; Seynaeve C; Devilee P; Salvesen HB; Dørum A; Hveem K; Vatten L; Lønning PE
    PLoS One; 2012; 7(4):e36263. PubMed ID: 22558411
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MDM2 SNP309 accelerates breast and ovarian carcinogenesis in BRCA1 and BRCA2 carriers of Jewish-Ashkenazi descent.
    Yarden RI; Friedman E; Metsuyanim S; Olender T; Ben-Asher E; Papa MZ
    Breast Cancer Res Treat; 2008 Oct; 111(3):497-504. PubMed ID: 18026875
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MDM2 SNP285 does not antagonize the effect of SNP309 in lung cancer.
    Ryan BM; Calhoun KM; Pine SR; Bowman ED; Robles AI; Ambs S; Harris CC
    Int J Cancer; 2012 Dec; 131(11):2710-6. PubMed ID: 22487911
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Contrasting effects of an Mdm2 functional polymorphism on tumor phenotypes.
    Ortiz GJ; Li Y; Post SM; Pant V; Xiong S; Larsson CA; El-Naggar AK; Johnson DG; Lozano G
    Oncogene; 2018 Jan; 37(3):332-340. PubMed ID: 28925402
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of breast cancer outcome with status of p53 and MDM2 SNP309.
    Boersma BJ; Howe TM; Goodman JE; Yfantis HG; Lee DH; Chanock SJ; Ambs S
    J Natl Cancer Inst; 2006 Jul; 98(13):911-9. PubMed ID: 16818855
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MDM2 SNP309, gene-gene interaction, and tumor susceptibility: an updated meta-analysis.
    Wan Y; Wu W; Yin Z; Guan P; Zhou B
    BMC Cancer; 2011 May; 11():208. PubMed ID: 21619694
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MDM2 promoter SNP55 (rs2870820) affects risk of colon cancer but not breast-, lung-, or prostate cancer.
    Helwa R; Gansmo LB; Romundstad P; Hveem K; Vatten L; Ryan BM; Harris CC; Lønning PE; Knappskog S
    Sci Rep; 2016 Sep; 6():33153. PubMed ID: 27624283
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lack of association between the MDM2-SNP309 polymorphism and breast cancer risk.
    Petenkaya A; Bozkurt B; Akilli-Ozturk O; Kaya HS; Gur-Dedeoglu B; Yulug IG
    Anticancer Res; 2006; 26(6C):4975-7. PubMed ID: 17214373
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Associations between the MDM2 promoter P1 polymorphism del1518 (rs3730485) and incidence of cancer of the breast, lung, colon and prostate.
    Gansmo LB; Vatten L; Romundstad P; Hveem K; Ryan BM; Harris CC; Knappskog S; Lønning PE
    Oncotarget; 2016 May; 7(19):28637-46. PubMed ID: 27081698
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.